Welcome to our dedicated page for Janux Therapeutics news (Ticker: JANX), a resource for investors and traders seeking the latest updates and insights on Janux Therapeutics stock.
Janux Therapeutics reports developments for a clinical-stage biopharmaceutical business focused on tumor-activated immunotherapies and immune-engaging drug candidates. The company applies its TRACTr, TRACIr and ARM platforms to programs in oncology and autoimmune disease, including PSMA-directed prostate cancer candidates and a CD19-targeted ARM candidate.
Recurring news themes include clinical progress for JANX007, JANX014 and JANX011, portfolio decisions such as the discontinued JANX008 program, financial results and business highlights, collaboration milestones with Bristol Myers Squibb, and leadership or governance updates tied to the company’s clinical development organization.
Janux Therapeutics (NASDAQ: JANX) has appointed Dr. Byron Robinson as Chief Strategy Officer. With 30 years of experience in the pharmaceutical industry, including leadership roles at Merck KGaA and Bayer, Dr. Robinson is expected to enhance Janux's clinical strategy and execution. His key contributions include overseeing late-stage development of oncology assets. Dr. Robinson's expertise will be pivotal as Janux advances its TRACTr and TRACIr platforms in developing innovative cancer immunotherapies.
Janux Therapeutics (NASDAQ: JANX) announced its participation in a virtual fireside chat at the H.C. Wainwright BioConnect Conference from January 10 to 13. The chat will be available for on-demand viewing starting January 10 at 7:00 a.m. ET on Janux's website. The company focuses on developing innovative immunotherapies using its TRACTr and TRACIr platforms, aimed at improving treatment for cancer patients. Key areas of development include T cell engagers targeting PSMA, EGFR, TROP2, and PD-L1xCD28, all in the IND-enabling or discovery stage.
Janux Therapeutics (Nasdaq: JANX) reported its third-quarter financials for 2021, showcasing a significant increase in cash reserves, totaling $387.5 million compared to $7.8 million as of December 2020. The company continues to advance its immunotherapy pipeline, with two IND filings planned for 2022 for the PSMA-TRACTr and EGFR-TRACTr candidates. However, Janux reported a net loss of $10.8 million this quarter, up from $1.3 million in the same period last year, influenced by increased R&D and operational costs.
Janux Therapeutics (NASDAQ: JANX) will participate in two virtual investor conferences. The first is Cowen’s 5th Annual IO Next Summit on November 15, 2021, from 12:15-12:35 p.m. ET. The second is the Evercore ISI 4th Annual Health CONx Conference on December 2, 2021, from 2:40-3:00 p.m. ET. Archived replays of both sessions will be available for about 90 days on Janux's website. Janux is focused on developing innovative immunotherapies using its TRACTr and TRACIr platforms to treat cancer, with products targeting various cancer-specific antigens.
Janux Therapeutics, Inc. (NASDAQ: JANX) announces the appointment of Ronald W. Barrett, Ph.D. and Alana McNulty to its Board of Directors. Dr. Barrett brings over 30 years of biopharmaceutical experience, having advanced multiple drug candidates to FDA approval. Ms. McNulty, with her extensive finance background, has managed transactions exceeding $2 billion. CEO David Campbell emphasizes their complementary expertise as vital for advancing Janux's cancer treatment programs. Janux focuses on innovative immunotherapies using its TRACTr and TRACIr platforms to treat solid tumors and is currently advancing several drug candidates.
Janux Therapeutics, Inc. (NASDAQ: JANX) announced its participation in the virtual H.C. Wainwright 23rd Annual Global Investor Conference from September 13-15, 2021. The corporate presentation will be accessible for on-demand viewing starting September 13 at 7:00 a.m. ET through Janux's website. Janux specializes in developing novel immunotherapies, focusing on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) technologies. Their lead programs target key cancer markers and aim to improve treatment efficacy for solid tumors.
Janux Therapeutics (Nasdaq: JANX) has appointed Dr. Shahram Salek-Ardakani as Chief Scientific Officer. Dr. Salek-Ardakani, with over 20 years in drug development, will spearhead the advancement of Janux's Tumor Activated T Cell Engager (TRACTr) platform technology. His expertise includes formulating innovative T-cell-targeted therapies at Pfizer. This leadership change aims to enhance Janux's pipeline of T cell engager immunotherapies designed to improve cancer treatment while minimizing toxicity. The TRACTr platform targets specific tumor markers to optimize efficacy and safety.
Janux Therapeutics, Inc. (Nasdaq: JANX) has successfully completed its initial public offering (IPO), closing on 13,110,000 shares at $17.00 per share. This includes 1,710,000 shares from the underwriters' full exercise of their option to purchase additional shares, totaling approximately $222.9 million in gross proceeds before expenses. The shares began trading on the Nasdaq Global Market on June 11, 2021. BofA Securities, Cowen, and Evercore ISI served as joint book-running managers for this offering.